These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 15328478)

  • 1. Endothelial markers and circulating angiogenic factors and p53 may be potential markers for recurrence in surgically resected non-small cell lung cancer patients.
    Brattström D; Bergqvist M; Wester K; Hesselius P; Ren ZP; Scheibenpflug L; Wagenius G; Brodin O
    Med Sci Monit; 2004 Sep; 10(9):BR331-8. PubMed ID: 15328478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody.
    Tanaka F; Otake Y; Yanagihara K; Kawano Y; Miyahara R; Li M; Yamada T; Hanaoka N; Inui K; Wada H
    Clin Cancer Res; 2001 Nov; 7(11):3410-5. PubMed ID: 11705856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology.
    Ludovini V; Pistola L; Gregorc V; Floriani I; Rulli E; Piattoni S; Di Carlo L; Semeraro A; Darwish S; Tofanetti FR; Stocchi L; Mihaylova Z; Bellezza G; Del Sordo R; Daddi G; Crinò L; Tonato M
    J Thorac Oncol; 2008 Apr; 3(4):365-73. PubMed ID: 18379354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Predicting efficacy of neoadjuvant cheomotherapy on resectable stage IIIA non-small cell lung cancer by multi-gene expressions].
    Cheng C; Wu YL; Gu LJ; Chen G; Weng YM; Feng WN; Zhong WZ
    Ai Zheng; 2005 Jul; 24(7):846-9. PubMed ID: 16004813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer.
    Giatromanolaki A; Koukourakis MI; Kakolyris S; Turley H; O'Byrne K; Scott PA; Pezzella F; Georgoulias V; Harris AL; Gatter KC
    Clin Cancer Res; 1998 Dec; 4(12):3017-24. PubMed ID: 9865915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Relevance of Endoglin (CD105) VEGF and p53 with invasion metastasis and prognosis of laryngeal carcinoma].
    Li Q; Zhang B; Peng P
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2007 Dec; 21(24):1114-7. PubMed ID: 18330257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic evaluation of the expression of p53 and bcl-2 oncoproteins in patients with surgically resected non-small cell lung cancer.
    Lai RS; Wang JS; Hsu HK; Chang HC; Lin CH; Lin MH
    Jpn J Clin Oncol; 2002 Oct; 32(10):393-7. PubMed ID: 12451034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of angiopoietins and its clinical significance in non-small cell lung cancer.
    Tanaka F; Ishikawa S; Yanagihara K; Miyahara R; Kawano Y; Li M; Otake Y; Wada H
    Cancer Res; 2002 Dec; 62(23):7124-9. PubMed ID: 12460935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological markers in non-small cell lung cancer. Retrospective study of 10 year follow-up after surgery.
    Carbognani P; Tincani G; Crafa P; Sansebastiano G; Pazzini L; Zoni R; Bobbio A; Rusca M
    J Cardiovasc Surg (Torino); 2002 Aug; 43(4):545-8. PubMed ID: 12124571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer.
    Gallardo E; Navarro A; Viñolas N; Marrades RM; Diaz T; Gel B; Quera A; Bandres E; Garcia-Foncillas J; Ramirez J; Monzo M
    Carcinogenesis; 2009 Nov; 30(11):1903-9. PubMed ID: 19736307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis.
    Dosaka-Akita H; Hu SX; Fujino M; Harada M; Kinoshita I; Xu HJ; Kuzumaki N; Kawakami Y; Benedict WF
    Cancer; 1997 Apr; 79(7):1329-37. PubMed ID: 9083154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer.
    Schneider PM; Praeuer HW; Stoeltzing O; Boehm J; Manning J; Metzger R; Fink U; Wegerer S; Hoelscher AH; Roth JA
    Br J Cancer; 2000 Aug; 83(4):473-9. PubMed ID: 10945494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytoplasmic Ape1 expression elevated by p53 aberration may predict survival and relapse in resected non-small cell lung cancer.
    Wu HH; Chu YC; Wang L; Tsai LH; Lee MC; Chen CY; Shieh SH; Cheng YW; Lee H
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S336-47. PubMed ID: 22688662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of circulating c-met messenger RNA is significantly correlated with nodal stage and early recurrence in non-small cell lung cancer.
    Cheng TL; Chang MY; Huang SY; Sheu CC; Kao EL; Cheng YJ; Chong IW
    Chest; 2005 Sep; 128(3):1453-60. PubMed ID: 16162743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low miR-145 and high miR-367 are associated with unfavourable prognosis in resected nonsmall cell lung cancer.
    Campayo M; Navarro A; Viñolas N; Diaz T; Tejero R; Gimferrer JM; Molins L; Cabanas ML; Ramirez J; Monzo M; Marrades R
    Eur Respir J; 2013 May; 41(5):1172-8. PubMed ID: 22835608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer.
    Mohamed S; Yasufuku K; Hiroshima K; Nakajima T; Yoshida S; Suzuki M; Sekine Y; Shibuya K; Iizasa T; Farouk A; Fujisawa T
    Cancer; 2007 Jun; 109(12):2506-14. PubMed ID: 17487846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of expression of p53 oncoprotein in primary (stage I-IIIa) non-small cell lung cancer.
    Tan DF; Li Q; Rammath N; Beck A; Wiseman S; Anderson T; al-Salameh A; Brooks J; Bepler G
    Anticancer Res; 2003; 23(2C):1665-72. PubMed ID: 12820438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical detection of p53 protein and prognosis of surgically resected non-small-cell lung cancer.
    Quantin X; Pujol JL; Lehmann M; Simony J; Serre I; Michel FB
    Cancer Detect Prev; 1997; 21(5):418-25. PubMed ID: 9307845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matrix metalloproteinase-2 status in stromal fibroblasts, not in tumor cells, is a significant prognostic factor in non-small-cell lung cancer.
    Ishikawa S; Takenaka K; Yanagihara K; Miyahara R; Kawano Y; Otake Y; Hasegawa S; Wada H; Tanaka F
    Clin Cancer Res; 2004 Oct; 10(19):6579-85. PubMed ID: 15475447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Y-box-binding protein-1 expression is not correlated with p53 expression but with proliferating cell nuclear antigen expression in non-small cell lung cancer.
    Yoshimatsu T; Uramoto H; Oyama T; Yashima Y; Gu C; Morita M; Sugio K; Kohno K; Yasumoto K
    Anticancer Res; 2005; 25(5):3437-43. PubMed ID: 16101161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.